National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Scientific academy / society / association


Location: Pittsburgh, PA, United States (USA) (US) US

ISNI: 0000000404337962

ROR: https://ror.org/05e2f9085

Show on Map:

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer (2023) Denkert C, Lambertini C, Fasching P, Pogue-Geile KL, Mano MS, Untch M, Wolmark N, et al. Journal article KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (2019) Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, et al. Journal article Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) Ingle JN, Kalari KR, Wickerham DL, Von Minckwitz G, Fasching P, Furukawa Y, Mushiroda T, et al. Journal article Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, et al. Journal article